ADIL FY2024 EPS Boosted by Litchfield Hills Research

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) – Analysts at Litchfield Hills Research raised their FY2024 EPS estimates for shares of Adial Pharmaceuticals in a research note issued to investors on Thursday, November 21st. Litchfield Hills Research analyst T. O’neill now expects that the company will earn ($1.31) per share for the year, up from their previous forecast of ($1.82). The consensus estimate for Adial Pharmaceuticals’ current full-year earnings is ($1.53) per share. Litchfield Hills Research also issued estimates for Adial Pharmaceuticals’ Q4 2024 earnings at ($0.37) EPS, Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.31) EPS and FY2025 earnings at ($1.33) EPS.

Other equities analysts have also recently issued research reports about the company. Rodman & Renshaw began coverage on Adial Pharmaceuticals in a report on Thursday, November 14th. They issued a “buy” rating and a $8.00 target price for the company. RODMAN&RENSHAW raised Adial Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, November 14th.

Adial Pharmaceuticals Stock Performance

Shares of NASDAQ:ADIL opened at $1.01 on Monday. Adial Pharmaceuticals has a 52-week low of $0.77 and a 52-week high of $4.17. The company has a fifty day moving average of $1.02 and a 200-day moving average of $1.10.

Institutional Trading of Adial Pharmaceuticals

An institutional investor recently bought a new position in Adial Pharmaceuticals stock. Virtu Financial LLC purchased a new stake in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 20,469 shares of the company’s stock, valued at approximately $27,000. Virtu Financial LLC owned about 0.48% of Adial Pharmaceuticals at the end of the most recent quarter. Institutional investors own 16.41% of the company’s stock.

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.